electroCore, Inc. (ECOR)

Market Cap	43.58M -58.0%
Revenue (ttm)	29.84M +27.9%
Net Income	-14.16M
EPS	-1.71
Shares Out	8.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,988
Open	5.10
Previous Close	5.07
Day's Range	5.10 - 5.57
52-Week Range	4.16 - 19.49
Beta	0.51
Analysts	Strong Buy
Price Target	22.00 (+303.67%)
Earnings Date	Mar 11, 2026

About ECOR

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electron...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: ECOR
• Website: https://www.electrocore.com

Financial Performance

In 2024, electroCore's revenue was $25.18 million, an increase of 57.09% compared to the previous year's $16.03 million. Losses were -$11.89 million, -36.89% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 303.67% from the latest price.

Price Target

$22.0

(303.67% upside)

Analyst Consensus: Strong Buy